Literature DB >> 29199721

Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1-3 positive axillary nodes postmastectomy: Development of a predictive nomogram.

T Wadasadawala1, S Kannan2, S Gudi1, A Rishi1, A Budrukkar1, V Parmar3, T Shet4, S Desai4, S Gupta5, R Badwe3, R Sarin1.   

Abstract

BACKGROUND: Role of postmastectomy radiotherapy (PMRT) in early breast cancer with 1-3 positive axillary nodes is still controversial. Hence, there is a need to identify subgroup of patients who have sufficiently high risk of disease recurrence to benefit from PMRT. AIM: The aim is to evaluate clinical outcomes of patients postmastectomy having pathological T1-T2 tumors with 1-3 positive axillary lymph nodes (LNs) treated with adjuvant systemic therapy and develop a predictive nomogram.
MATERIALS AND METHODS: Data collected retrospectively from eligible patients from 2005 to 2011. Kaplan-Meier survival analysis was used for all time-to-event analysis. Various known clinical and pathological risk factors were correlated with outcome using uni- and multi-variable analysis in SPSS version 21. All comparisons were two-tailed and P < 0.05 were considered statistically significant. The nomogram to predict the risk of loco-regional control (LRC) was developed using least absolute shrinkage and selection operator shrinkage model in hdnom.io software.
RESULTS: 38/242 (15.7%) patients had recurrent disease at loco-regional (10 patients), distant sites (22 patients) and simultaneous loco-regional and distant sites (6 patients) at a median follow-up 59.5 (range 4-133) months. Five years estimate of LRC, distant disease-free survival (DFS), DFS, cause-specific survival and overall survival was 87.8%, 85.4%, 84.2%, 93.1%, and 91.5%, respectively. Pathological tumor size, margin status, LN ratio as continuous variables and grade and triple negative breast cancer status as categorical variables were the risk factors included in the model for building nomogram.
CONCLUSION: The nomogram developed based on institutional data can be a valuable tool in guiding adjuvant PMRT depending on the risk of 5 years loco-regional recurrence.

Entities:  

Mesh:

Year:  2017        PMID: 29199721     DOI: 10.4103/ijc.IJC_178_17

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  4 in total

1.  Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands.

Authors:  Cornelia D van Steenbeek; Marissa C van Maaren; Sabine Siesling; Annemieke Witteveen; Xander A A M Verbeek; Hendrik Koffijberg
Journal:  BMC Med Res Methodol       Date:  2019-06-08       Impact factor: 4.615

2.  Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.

Authors:  Yuxi Zhang; Zhipeng Xu; Hui Chen; Xinchen Sun; Zhaoyue Zhang
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

3.  The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype.

Authors:  Jinli Wei; Yizhou Jiang; Zhimin Shao
Journal:  Breast       Date:  2020-03-12       Impact factor: 4.380

4.  A Nomogram Based on Radiomics with Mammography Texture Analysis for the Prognostic Prediction in Patients with Triple-Negative Breast Cancer.

Authors:  Xian Jiang; Xiuhe Zou; Jing Sun; Aiping Zheng; Chao Su
Journal:  Contrast Media Mol Imaging       Date:  2020-08-25       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.